Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
Riccardo MoiaChiara FaviniValentina FerriGabriela ForestieriLodovico Terzi Di BergamoMattia SchipaniSruthi SagirajuAnnalisa AndornoSilvia RasiRamesh AdhinaveniDonatella TalottaWael Al EssaLorenzo De PaoliGloria Margiotta CasaluciAndrea PatriarcaRenzo L BoldoriniDavide RossiGianluca GaidanoPublished in: British journal of haematology (2021)
We aimed at molecularly dissecting the anatomical heterogeneity of small lymphocytic lymphoma (SLL), by analysing a cohort of 12 patients for whom paired DNA from a lymph node biopsy and circulating cells, as well as plasma-circulating tumour DNA (ctDNA) was available. Notably, the analyses of the lymph node biopsy and of circulating cells complement each other since a fraction of mutations (20·4% and 36·4%, respectively) are unique to each compartment. Plasma ctDNA identified two additional unique mutations. Consistently, the different synchronous sources of tumour DNA complement each other in informing on driver gene mutations in SLL harbouring potential prognostic and/or predictive value.
Keyphrases
- circulating tumor
- lymph node
- cell free
- induced apoptosis
- single molecule
- circulating tumor cells
- single cell
- cell cycle arrest
- diffuse large b cell lymphoma
- end stage renal disease
- ejection fraction
- nucleic acid
- newly diagnosed
- ultrasound guided
- cell death
- signaling pathway
- endoplasmic reticulum stress
- sentinel lymph node
- cell proliferation
- drinking water
- early stage
- fine needle aspiration
- patient reported outcomes
- risk assessment